ESMO Guidelines in SilverCancer

What are ESMO Clinical Practice Guidelines?

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines are the reference standard for evidence-based oncology practice in Europe and increasingly globally. They reflect EMA drug approvals, European reimbursement contexts, and are updated regularly as evidence evolves. ESMO Clinical Practice Guidelines are publicly available and are the primary oncology guideline reference used by SilverCancer for European queries.

Evidence levels and recommendation grades

Evidence Level	Source
I	Large RCT of good quality, or meta-analyses without heterogeneity
II	Small RCTs or large RCTs with suspicion of bias; meta-analyses with heterogeneity
III	Prospective cohort studies
IV	Retrospective cohort or case-control studies
V	Studies without control group, case reports, expert opinions

Grade	Recommendation
A	Strong evidence for efficacy with substantial clinical benefit — strongly recommended
B	Strong or moderate evidence for efficacy with limited clinical benefit — generally recommended
C	Insufficient evidence or benefit does not outweigh risk — optional
D	Moderate evidence against efficacy — generally not recommended
E	Strong evidence against efficacy — never recommended

Guidelines covered

SilverCancer indexes all current ESMO CPGs across major tumour types: breast, NSCLC and SCLC, colorectal and gastric, pancreatic and hepatocellular, prostate, urothelial and renal cell, melanoma, head and neck, gynaecological cancers, haematological malignancies (EHA–ESMO), sarcomas, thyroid and neuroendocrine tumours, brain tumours, cancer of unknown primary, supportive and palliative care.

Integration in Copilot

SilverCancer displays ESMO recommendation grade and evidence level alongside the GRADE certainty assessment. Where ESMO diverges from national guidelines due to reimbursement constraints, this is flagged explicitly — because the question is often not what ESMO recommends, but what is available to the specific patient.

Update frequency

ESMO Living Guidelines are indexed continuously. Standard CPGs are indexed within 72 hours of publication. The guideline version date is always displayed alongside any recommendation.